Legal & General Group
SION

Legal & General Group’s Sionna Therapeutics SION Stock Holding History

Legal & General Group’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$398K Buy
9,044
+7,612
+532% +$305K ﹤0.01% 2451
2026
Q1 		$57.4K Sell
1,432
-250
-15% -$9.54K ﹤0.01% 2657
2025
Q4 		$69.2K Sell
1,682
-5,692
-77% -$216K ﹤0.01% 2671
2025
Q3 		$217K Buy
7,374
+6,000
+437% +$131K ﹤0.01% 2581
2025
Q2 		$23.8K Buy
+1,374
New +$18K ﹤0.01% 2937

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Legal & General Group's SION Position: Q2 2026 in Review

Legal & General Group increased its Sionna Therapeutics (SION) stake by 532% in Q2 2026, buying an estimated $305K and bringing the position to 9,044 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #2451.

Legal & General Group first reported a position in SION in Q2 2025 and has held it in 5 quarters since. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Legal & General Group held 9,044 shares of Sionna Therapeutics worth $398K as of Q2 2026.
  • Legal & General Group bought 7,612 Sionna Therapeutics shares in Q2 2026, an estimated $305K.
  • Sionna Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2451 holding.
  • Legal & General Group first reported a position in Sionna Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.